/
Immunology
Ulcerative Colitis
102
Pipeline Programs↗
201
Active Trials↗
111
Companies Involved↗
Ulcerative Colitis is a highly competitive landscape with 102 programs across 111 companies. The most active players are Pfizer, Sanofi, Spyre Therapeutics, Inc.. 27 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical32
Phase 112
Phase 231
Phase 327
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
73 of 83 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 83 classified programs, each share of the total. Modality classified for 85% of 102 pipeline programs.
Analysis
Trial Status
729
clinical trials
Completed345 · 47%
Recruiting107 · 15%
Terminated100 · 14%
Unknown status54 · 7%
Active, not recruiting46 · 6%
Not yet recruiting41 · 6%
Other36 · 5%
Clinical Trials
Trial Activity
729 trials
The Efficacy of Lactobacillous Probiotic and Trace Elements in the Management of Ulcerative Colitis Patients
Recruiting·NNational Hepatology & Tropical Medicine Research Institute·Approved·NCT07758335·132 enrolled
Page 1 of 49
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)